The Evolving Treatment Options For CLL, From ‘Watchful Waiting’ To New Targeted Combinations

CLL is the most common form of leukemia and it behaves unlike most cancers people picture. It’s often slow, and many people live with it for years.

Despite incredible advances in the past decade, the best treatment approach for some patients after diagnosis is to simply watch and wait.

The ‘Watch and Wait’ Approach

If your disease is early and you don’t have symptoms, the recommended approach is often no treatment at all, just careful monitoring. Doctors call it “watch and wait.”

It sounds like doing nothing, but it isn’t.

“We see it is a condition that I tell the patients it’s more like hypertension or diabetes. Like if you have a diagnosis of diabetes, some people can control it with just diet and exercise, whereas some other patients need to take a pill, and some other patients need insulin. So it’s the same. Think about it as a chronic disease,” Dr. Barrientos says.

Large studies have tested treating early, symptom-free CLL right away, and none of them showed that patients lived longer. Ultimately, starting sooner can expose people to side effects for no gain.

“The toxicities of the interventions that we do may do more harm and not [lead to] a longer life than just living with the condition,” Dr. Barrientos says. “About a third of the patients may never require treatment throughout their lifespan.”

How Has Treatment Changed?

In the past, when treatment was needed, the old standard was chemotherapy, often combined with an antibody, in regimens known by initials like FCR or BR. These worked, and for one genetic subgroup, they worked remarkably well, producing very long remissions. But chemo hits healthy cells along with cancer cells, which means it often causes difficult side effects.

Now, over the past decade, targeted therapies that spare healthy cells have been developed — and completely changed treatment.

“We’re very happy to say that people can live a normal life without chemotherapy. So all of these are targeted agencies, essentially like warheads. They just go and kill what they need to kill without doing too much damage,” Dr. Barrientos says.

Instead of poisoning fast-dividing cells broadly, researchers found ways to switch off the specific signals CLL cells depend on to survive. Two families of drugs changed everything: BTK inhibitors and BCL-2 inhibitors.

Targeted Drugs for CLL

BTK inhibitors block a protein called BTK. The original drug in this class, ibrutinib (brand name Imbruvica), proved that a daily pill could control CLL, even in patients whose genetics made chemo nearly useless. That was a genuine breakthrough.

But ibrutinib carried some heart-related side effects, including irregular heartbeat and high blood pressure. So newer versions were built to be cleaner. Acalabrutinib (brand name Calquence) and zanubrutinib (brand name Brukinsa) hit the same target with fewer off-target effects, and in head-to-head trials they proved both effective and easier on the heart.

The second family of drugs block a survival protein called BCL-2. Its main drug, venetoclax (brand name Venclexta or Venclyxto), does something the BTK pills usually don’t: it drives the disease down to levels so low that sensitive tests can’t detect any leukemia left. Doctors call that “undetectable minimal residual disease,” and it’s become one of the most important goals of modern treatment.

“Now we have drugs that we can combine and mix and get them a good quality of life, which is what we want. Right? You don’t want to be in remission and then fall out. You want something that can get you into a deep remission and get you off any therapy. And if you can … go on with your life without having to deal with toxicities,” Dr. Barrientos says.

Continuous v. Time-Limited Treatments

BTK inhibitors, taken alone, are usually meant to continue indefinitely. You keep taking the pill. Venetoclax, especially paired with an antibody like obinutuzumab (brand name Gazyva), is given for a fixed stretch of time, often about a year, and then you stop.

A break from treatment is beneficial for many reasons — it means fewer cumulative side effects and lower long-term cost.

Trials of venetoclax-based combinations have shown deep, durable remissions that hold up well after the drugs are done. Increasingly, doctors are combining the two targeted families together for a set period, aiming to hit the disease hard, reach that undetectable state, and then give patients their lives back for a while.

“It comes with its own toxicities, and patients need to understand the trade‑offs,” Dr. Barrientos says. “For older patients, those in their 80s or 90s who are already taking multiple medications, adding a daily pill doesn’t usually bother them.”

Younger patients often feel differently. “They usually tell me they don’t want to take a pill forever,” Dr. Barrientos says. “They prefer a time‑limited approach that lets them get back to themselves without constantly thinking about the disease.”

These fixed-duration combinations are genuinely impressive, but researchers are honest that we don’t yet know whether they cure CLL. Long remission is not the same as a cure, and good doctors will tell you that plainly.

Understanding Your Prognosis

In the U.S., the five-year survival rate for people with CLL is about 90%, according to the National Cancer Institute, and that rate has been steadily trending upwards over the past 15 or so years.

The improvement reflects the progress described here. But a word of caution: that number blends together people with very mild disease and people with aggressive disease. It is not a prediction about any single person.

Outlook depends on each patient’s:

• Stage
• Genetics
• Disease behavior

Not every story is tidy. Some patients eventually stop responding to both drug families: a situation called “double refractory.”

For them, standard options run thin, and that’s an area of real, unfinished medical need. But it’s also where the next wave of research is concentrated.

Newer BTK drugs like pirtobrutinib and CAR T-cell therapy are already approved for people who’ve exhausted the standard drugs, while BTK degraders and bispecific antibodies remain in trials.

Questions To Ask Your Doctor

• How will we determine when it’s the “right” time to treat my CLL?
• What are the risks and benefits of a “watch and wait” approach?
• Which class or combination of drugs do you recommend in my case?
• Are there any clinical trials I should consider joining?

Learn more about SurvivorNet's rigorous medical review process.

---